Look back at pharma news in week to July 13

Deal-making news last week included Benitec Biopharma’s collaboration with Axovant Sciences on rare disease drug BB-301, which sent the Australian firm’s shares more than doubling. On the M&A front, BioCryst’s merger with Idera was resisted by shareholders. Company news included disappointment for Regulus Therapeutics when it paused clinical studies and slashed its work force. Also attracting attention was Pfizer’s announcement to defer planned drug price hikes and Pfizer’s decision to reorganize its business.

Not developing your gene therapy? Call Axovant

If you run a small-cap biotech company and have a gene therapy asset languishing in your patent portfolio then this could be your lucky day: Axovant is buying, commented EP Vantage, the editorial arm of the Evaluate group.